Your session is about to expire
← Back to Search
Mivavotinib for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is testing a new cancer drug to see if it's effective in treating patients with a certain type of aggressive lymphoma. NGS will be used to identify patients who may benefit the most from the drug.
- MyD88 and CD79B Mutations
- Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How does Mivavotinib impact the safety of individuals?
"As the trial is currently in Phase 2, prior evidence of safety has been established but there are no guarantees that mivavotinib will be efficacious. We rate its safety as a 2 on our scale from 1 to 3."
Are elderly individuals (over 85) being accepted for this clinical investigation?
"Eligibility for this medical trial is limited to adults aged 18-100. Conversely, there are 304 clinical trials available for patients below the age of consent and 1607 studies designated specifically towards seniors over 65 years old."
Does my profile qualify me for participation in this experiment?
"This medical trial seeks out 50 individuals with b-lymphocytes ranging between 18 and 100 in age. The fundamental requirements for recruitment are; Gender of either male or female, Eastern Cooperative Oncology Group (ECOG) Performance Status rating at 0 to 2, Expectancy of life that exceeds 3 months, Histologically confirmed de novo or transformed non-GCB DLBCL., Relapsed or refractory to ≥ 2 prior lines of chemotherapy based on standard of care, No more than 5 previous treatments failed by the patient, [18F]Fluorodeoxyglucose-positron emission tomography ("
How extensive is the geographic reach of this experiment?
"Currently, there are 6 clinical trial sites hosting this research. These medical centres are located in Philadelphia, Houston and Evanston among other cities; thus it is wise to choose the nearest option to reduce travel time if you commit to being a participant."
Are researchers still recruiting for this investigation?
"Affirmative, the clinicaltrials.gov records suggest that this medical experiment is currently recruiting patients. This trial was initiated on June 23rd 2022 and modified most recently on November 7th of the same year. For successful recruitment, 50 individuals need to enrol from 6 dissimilar sites."
How many applicants are being accepted into the experiment?
"Indeed, the information accessible on clinicaltrials.gov suggests that this trial is actively recruiting patients. This study was unveiled in June of 2022 and its details were most recently revised in November of the same year. The research team seeks to enlist 50 individuals from 6 distinct sites."
Share this study with friends
Copy Link
Messenger